EVGN

Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs Cash burn expected to decline to approximately $8.5–$9.5 million in 2026, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024  Second-quarter net loss was reduced to approximately $1.8 million, compared with approximately $4.7 million in the second quarter of 2025 and approximately $6.0 million in the second quarter of 2024 Six active drug development collaborations established with biotechnology companies and leading academic institutions Virtual chemical space expanded to approximately 110 billion molecules, supported by advanced AI models and autonomous AI Agents REHOVOT, Israel, Aug. 18, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first half of 2026 and second quarter ended June 30, 2026, and provided an update on its strategic and operational progress.

Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that its Chairman, Nir Nimrodi, will join the Company's upcoming quarterly results conference call on August 18, 2026.

Zoom conference call scheduled for August 18, 2026, 9:00 AM ET REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the second quarter 2026, on Tuesday , August 18 , 2026.

Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July 22, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and ELEO Inc., a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.

New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success  at early discovery stages REHOVOT, Israel, July 15, 2026 /PRNewswire/ -- AgPlenus Ltd., a company developing novel, sustainable crop protection products and a subsidiary of Evogene Ltd.

Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities REHOVOT, ISRAEL and TEL AVIV, ISRAEL, July 8, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University, today announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel's academic research ecosystem and focused on small-molecule drug discovery.

Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing the likelihood of success. REHOVOT, Israel, June 24, 2026 /PRNewswire/ -- Evogene Ltd.

Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, USA.

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd.

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript